Update on PDP-716 NDA
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SPARC's licensing partner Ocuvex Therapeutics has received a Complete Response Letter (CRL) from the US FDA for the PDP-716 New Drug Application. The FDA issued the CRL due to inspection findings at the finished product manufacturing facility. Importantly, the FDA did not raise any other issues with the PDP-716 NDA itself, meaning the drug candidate cleared most regulatory hurdles. The company has not disclosed when or if they plan to address the manufacturing facility issues and resubmit the application.
This is a regulatory setback as the NDA cannot be approved until manufacturing facility issues are resolved. The stock may face negative sentiment in the short term, though the absence of drug-related concerns provides some comfort for long-term investors.